Cargando…

Inhomogeneous Diastereomeric Composition of Mongersen Antisense Phosphorothioate Oligonucleotide Preparations and Related Pharmacological Activity Impairment

Mongersen is a 21-mer antisense oligonucleotide designed to downregulate Mothers against decapentaplegic homolog 7 (SMAD7) expression to treat Crohn's disease. Mongersen was manufactured in numerous batches at different scales during several years of clinical development, which all appeared ide...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arrico, Lorenzo, Stolfi, Carmine, Marafini, Irene, Monteleone, Giovanni, Demartis, Salvatore, Bellinvia, Salvatore, Viti, Francesca, McNulty, Marie, Cabani, Irene, Falezza, Anita, Di Bari, Lorenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mary Ann Liebert, Inc., publishers 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9416542/ https://www.ncbi.nlm.nih.gov/pubmed/35263186 http://dx.doi.org/10.1089/nat.2021.0089

Ejemplares similares

A Novel Smad7 Genetic Variant Mapping on the Genomic Region Targeted by Mongersen Is Associated with Crohn’s Disease
por: Di Fusco, Davide, et al.
Publicado: (2020)

A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohn’s Disease: A Phase II, Open-Label Study
por: Marafini, Irene, et al.
Publicado: (2021)

Smad7 Antisense Oligonucleotide-Based Therapy in Crohn's Disease: Is it Time to Re-Evaluate?
por: Monteleone, Giovanni, et al.
Publicado: (2022)

Impact of patient characteristics on the clinical efficacy of mongersen (GED‐0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease
por: Monteleone, G., et al.
Publicado: (2016)

Association Between Celiac Disease and Cancer
por: Marafini, Irene, et al.
Publicado: (2020)

Transforming Growth Factor-β1/Smad7 in Intestinal Immunity, Inflammation, and Cancer
por: Troncone, Edoardo, et al.
Publicado: (2018)

Involvement of Smad7 in Inflammatory Diseases of the Gut and Colon Cancer
por: Troncone, Edoardo, et al.
Publicado: (2021)

Role of TGF-Beta and Smad7 in Gut Inflammation, Fibrosis and Cancer
por: Stolfi, Carmine, et al.
Publicado: (2020)

Helicobacter pylori and Gastric Cancer: Pathogenetic Mechanisms
por: Salvatori, Silvia, et al.
Publicado: (2023)

Antisense Oligonucleotide: Basic Concepts and Therapeutic Application in Inflammatory Bowel Disease
por: Di Fusco, Davide, et al.
Publicado: (2019)

The Dual Role of Smad7 in the Control of Cancer Growth and Metastasis
por: Stolfi, Carmine, et al.
Publicado: (2013)

Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes
por: Koller, Erich, et al.
Publicado: (2011)

Controlled sulfur-based engineering confers mouldability to phosphorothioate antisense oligonucleotides
por: Genna, Vito, et al.
Publicado: (2023)

Smad7 Antisense Oligonucleotide in Crohn’s Disease: A Re-Evaluation and Explanation for the Discordant Results of Clinical Trials
por: Monteleone, Giovanni, et al.
Publicado: (2022)

NPD-0414-2 and NPD-0414-24, Two Chemical Entities Designed as Aryl Hydrocarbon Receptor (AhR) Ligands, Inhibit Gut Inflammatory Signals
por: Marafini, Irene, et al.
Publicado: (2019)

Nucleic acid binding proteins affect the subcellular distribution of phosphorothioate antisense oligonucleotides
por: Bailey, Jeffrey K., et al.
Publicado: (2017)

Membrane Destabilization Induced by Lipid Species Increases Activity of Phosphorothioate-Antisense Oligonucleotides
por: Wang, Shiyu, et al.
Publicado: (2018)

Mesyl phosphoramidate antisense oligonucleotides as an alternative to phosphorothioates with improved biochemical and biological properties
por: Miroshnichenko, S. K., et al.
Publicado: (2019)

Dynamic Diastereomerism on Chiral Surfaces
por: Matysik, Sabine C., et al.
Publicado: (2022)

Characterizing the effect of GalNAc and phosphorothioate backbone on binding of antisense oligonucleotides to the asialoglycoprotein receptor
por: Schmidt, Karsten, et al.
Publicado: (2017)

Solid-Phase Synthesis of Boranophosphate/Phosphorothioate/Phosphate Chimeric Oligonucleotides and Their Potential as Antisense Oligonucleotides
por: Takahashi, Yuhei, et al.
Publicado: (2021)

Therapeutic Oligonucleotides for Patients with Inflammatory Bowel Diseases
por: Marafini, Irene, et al.
Publicado: (2020)

Precision Medicine in Inflammatory Bowel Diseases
por: Marafini, Irene, et al.
Publicado: (2021)

Smoking and colorectal cancer in inflammatory bowel disease: Quantity matters?
por: Marafini, Irene, et al.
Publicado: (2023)

Electronic Structures of LNA Phosphorothioate Oligonucleotides
por: Bohr, Henrik G., et al.
Publicado: (2017)

Structure Activity Relationships of α-L-LNA Modified Phosphorothioate Gapmer Antisense Oligonucleotides in Animals
por: Seth, Punit P, et al.
Publicado: (2012)

Bolaamphiphile-based nanocomplex delivery of phosphorothioate gapmer antisense oligonucleotides as a treatment for Clostridium difficile
por: Hegarty, John P, et al.
Publicado: (2016)

Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides
por: Østergaard, Michael E, et al.
Publicado: (2020)

NMR and EPR Study of Homolysis of Diastereomeric Alkoxyamines
por: Cherkasov, Sergey, et al.
Publicado: (2020)

Self-Sorting in Diastereomeric Mixtures of Functionalized Dipeptides
por: Guan, Qingwen, et al.
Publicado: (2023)

Translation of stable hepadnaviral mRNA cleavage fragments induced by the action of phosphorothioate-modified antisense oligodeoxynucleotides
por: Hasselblatt, Peter, et al.
Publicado: (2005)

Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages
por: Wan, W. Brad, et al.
Publicado: (2014)

Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2′-modifications and enhances antisense activity
por: Liang, Xue-Hai, et al.
Publicado: (2016)

Intra-endosomal trafficking mediated by lysobisphosphatidic acid contributes to intracellular release of phosphorothioate-modified antisense oligonucleotides
por: Wang, Shiyu, et al.
Publicado: (2017)

Accessible light-controlled knockdown of cell-free protein synthesis using phosphorothioate-caged antisense oligonucleotides
por: Hartmann, Denis, et al.
Publicado: (2023)

Respiratory Tract Infections in Inflammatory Bowel Disease Patients Taking Vedolizumab: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Marafini, Irene, et al.
Publicado: (2021)

Long-term Exon Skipping Studies With 2′-O-Methyl Phosphorothioate Antisense Oligonucleotides in Dystrophic Mouse Models
por: Tanganyika-de Winter, Christa L, et al.
Publicado: (2012)

Preclinical PK and PD Studies on 2′-O-Methyl-phosphorothioate RNA Antisense Oligonucleotides in the mdx Mouse Model
por: Heemskerk, Hans, et al.
Publicado: (2010)

Stabilin-1 and Stabilin-2 are specific receptors for the cellular internalization of phosphorothioate-modified antisense oligonucleotides (ASOs) in the liver
por: Miller, Colton M., et al.
Publicado: (2016)

Cellular uptake mediated by epidermal growth factor receptor facilitates the intracellular activity of phosphorothioate-modified antisense oligonucleotides
por: Wang, Shiyu, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_qoa64gt750p0pu8b9t7cikf2rm